ClinicalTrials.Veeva

Menu
C

Core Clinical Research | Everett, WA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Azetukalner
Cariprazine
ABBV-932
Lumateperone
BI 1358894
Lasmiditan
Atogepant
LY573144
Brexpiprazole
SP-624

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

23 of 59 total trials

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)

A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized...

Active, not recruiting
Generalized Anxiety Disorder
Drug: DT120
Other: Placebo

X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult part...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo
Drug: Azetukalner

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: Azetukalner

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in pat...

Enrolling
Depression in Adults
Depression Disorders
Drug: CYB003
Behavioral: Psychological Support

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Active, not recruiting
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Icalcaprant
Drug: Placebo for Icalcaprant

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling
Bipolar I Disorder
Depression
Drug: Placebo
Drug: Cariprazine

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and se...

Enrolling
Major Depressive Disorder
Drug: Icalcaprant
Drug: Placebo for Icalcaprant

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling
Episodic Migraine
Drug: Placebo-Matching Atogepant
Drug: Atogepant
Recently updated

The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to \[...

Active, not recruiting
Tourette Syndrome
Drug: Ecopipam

The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on...

Active, not recruiting
Depressive Disorder, Major
Drug: JNJ-89495120
Drug: Placebo

X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participa...

Invitation-only
Bipolar II Disorder
Bipolar I Disorder
Drug: Azetukalner

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Invitation-only
Major Depressive Disorder
Drug: Azetukalner

Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)

Active, not recruiting
Treatment Resistant Depression
Drug: Psilocybin

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only
Migraine Prophylaxis
Drug: Atogepant

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs)...

Enrolling
Bipolar Depression
Drug: Lumateperone
Drug: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irrita...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Lumateperone low dose
Drug: Lumateperone high dose

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophren...

Enrolling
Autism Spectrum Disorder
Schizophrenia
Drug: Lumateperone

Trial sponsors

AbbVie logo
Otsuka logo
Janssen (J&J Innovative Medicine) logo
Boehringer Ingelheim logo
X
Intra-Cellular Therapies logo
E
E
Lilly logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems